Appears on
Articles3
ABPI analysis on NICE’s changes for evaluating new medicines: Next steps
Commentary on the publication of NICE's Manual which sets out how the latest medicines and health technologies will be evaluated.
0
ABPI Blogs and News4d agoInnovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
0
ABPI Blogs and News4d agoGreater ambition is needed to improve patient access to innovative medicines
The government is consulting on changes to the Commercial Framework for New Medicines and the Budget Impact Test threshold. In this article, Paul Catchpole, ABPI’s Director of Value and Access Policy, sets out why this is important and what needs to change.
0
ABPI Blogs and News3d ago